Artelo Biosciences, Inc. (ARTL)
- Previous Close
1.3100 - Open
1.3100 - Bid --
- Ask --
- Day's Range
1.2898 - 1.3418 - 52 Week Range
1.1500 - 2.9800 - Volume
5,402 - Avg. Volume
14,962 - Market Cap (intraday)
4.331M - Beta (5Y Monthly) 1.20
- PE Ratio (TTM)
-- - EPS (TTM)
-3.1400 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.67
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
www.artelobio.comRecent News: ARTL
Performance Overview: ARTL
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARTL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARTL
Valuation Measures
Market Cap
4.33M
Enterprise Value
-6.07M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.37
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.65
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-37.09%
Return on Equity (ttm)
-59.63%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-9.29M
Diluted EPS (ttm)
-3.1400
Balance Sheet and Cash Flow
Total Cash (mrq)
10.43M
Total Debt/Equity (mrq)
0.20%
Levered Free Cash Flow (ttm)
-4.64M